Related references
Note: Only part of the references are listed.Apoptotic Sensitivity of Colon Cancer Cells to Histone Deacetylase Inhibitors Is Mediated by an Sp1/Sp3-Activated Transcriptional Program Involving Immediate-Early Gene Induction
Andrew J. Wilson et al.
CANCER RESEARCH (2010)
Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma
Takashi Watanabe et al.
CANCER SCIENCE (2010)
Epigenetics and transgenerational transfer: a physiological perspective
D. H. Ho et al.
JOURNAL OF EXPERIMENTAL BIOLOGY (2010)
SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer
Veronica Novotny-Diermayr et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation
E. Borbone et al.
ONCOGENE (2010)
Histone deacetylases and the immunological network: implications in cancer and inflammation
A. Villagra et al.
ONCOGENE (2010)
Epigenetics: molecular mechanisms and implications for disease
Adam E. Handel et al.
TRENDS IN MOLECULAR MEDICINE (2010)
Histone Deacetylase Inhibitors: Design, Structure-Activity Relationships and Therapeutic Implications for Cancer
Charles M. Marson
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2009)
Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors
Annunziata Gloghini et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Histone deacetylase inhibitors that target tubulin
Joerg Schemies et al.
CANCER LETTERS (2009)
Biomarkers for predicting clinical responses to HDAC inhibitors
Lindsay Stimson et al.
CANCER LETTERS (2009)
Histone deacetylase inhibitors and genomic instability
Gregory Eot-Houllier et al.
CANCER LETTERS (2009)
Development of vorinostat: Current applications and future perspectives for cancer therapy
Victoria M. Richon et al.
CANCER LETTERS (2009)
Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer
Oronza Antonietta Botrugno et al.
CANCER LETTERS (2009)
Isoform-specific histone deacetylase inhibitors: The next step?
Sriram Balasubramanian et al.
CANCER LETTERS (2009)
Enhancing the apoptotic and therapeutic effects of HDAC inhibitors
Ailsa J. Frew et al.
CANCER LETTERS (2009)
Targeting tumor angiogenesis with histone deacetylase inhibitors
Leigh Ellis et al.
CANCER LETTERS (2009)
Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
Peter Atadja
CANCER LETTERS (2009)
Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors
Yutaka Fujiwara et al.
CANCER SCIENCE (2009)
Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells
S. Lee et al.
CELL PROLIFERATION (2009)
Preclinical Studies of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytosine Arabinoside and Etoposide for Treatment of Acute Leukemias
Ken Shiozawa et al.
CLINICAL CANCER RESEARCH (2009)
Epigenetic Modifiers: Basic Understanding and Clinical Development
Richard L. Piekarz et al.
CLINICAL CANCER RESEARCH (2009)
Rational Combinations Using HDAC Inhibitors
Michael Bots et al.
CLINICAL CANCER RESEARCH (2009)
JNJ-26481585, a Novel Second-Generation Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity
Janine Arts et al.
CLINICAL CANCER RESEARCH (2009)
Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise
Antonello Mai et al.
CURRENT PHARMACEUTICAL DESIGN (2009)
Targeting Histone Deacetylase Inhibitors for Anti-Malarial Therapy
Katherine T. Andrews et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2009)
Novel Structural Insights into Class I and II Histone Deacetylases
Ralf Ficner
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2009)
Histone Deacetylase Inhibitors Current Status and Overview of Recent Clinical Trials
Xujun Ma et al.
DRUGS (2009)
Targeting of HDAC8 and investigational inhibitors in neuroblastoma
Ina Oehme et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
New patented histone deacetylase inhibitors
Haishan Wang et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2009)
Histone Deacetylase Inhibitors: Potential in Cancer Therapy
P. A. Marks et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2009)
Lack of Therapeutic Effect of the Histone Deacetylase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid Carcinoma
Jennifer A. Woyach et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
Evanthia Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
Richard L. Piekarz et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Design of Chimeric Histone Deacetylase- and Tyrosine Kinase-Inhibitors: A Series of Imatinib Hybrides as Potent Inhibitors of Wild-Type and Mutant BCR-ABL, PDGF-Rβ, and Histone Deacetylases
Siavosh Mahboobi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Pharmacologic Resuscitation: Cell Protective Mechanisms of Histone Deacetylase Inhibition in Lethal Hemorrhagic Shock
Muhammad U. Butt et al.
JOURNAL OF SURGICAL RESEARCH (2009)
Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma
Suresh S. Ramalingam et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Histone Deacetylase Inhibitor Induction of P-Glycoprotein Transcription Requires Both Histone Deacetylase 1 Dissociation and Recruitment of CAAT/Enhancer Binding Protein β and pCAF to the Promoter Region
Su-Nam Kim et al.
MOLECULAR CANCER RESEARCH (2009)
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
Douglas C. Marchion et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Epigenetics in cancer: Targeting chromatin modifications
Leigh Ellis et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Glucose Metabolism as a Target of Histone Deacetylase Inhibitors
Suzanne E. Wardell et al.
MOLECULAR ENDOCRINOLOGY (2009)
The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance
Alejandro Villagra et al.
NATURE IMMUNOLOGY (2009)
The many roles of histone deacetylases in development and physiology: implications for disease and therapy
Michael Haberland et al.
NATURE REVIEWS GENETICS (2009)
Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients
Hao-Hueng Chang et al.
ORAL ONCOLOGY (2009)
HDAC4 Regulates Neuronal Survival in Normal and Diseased Retinas
Bo Chen et al.
SCIENCE (2009)
MicroRNA-206 Delays ALS Progression and Promotes Regeneration of Neuromuscular Synapses in Mice
Andrew H. Williams et al.
SCIENCE (2009)
Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
Chunaram Choudhary et al.
SCIENCE (2009)
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
M. Crump et al.
ANNALS OF ONCOLOGY (2008)
Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?
L. Nolan et al.
BRITISH JOURNAL OF CANCER (2008)
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas
Lia Gore et al.
CLINICAL CANCER RESEARCH (2008)
Clinical and molecular responses in lung cancer patients receiving Romidepsin
David S. Schrump et al.
CLINICAL CANCER RESEARCH (2008)
A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors
Nicola L. Steele et al.
CLINICAL CANCER RESEARCH (2008)
A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study
Thehang H. Luu et al.
CLINICAL CANCER RESEARCH (2008)
Chemical Origins of Isoform Selectivity in Histone Deacetylase Inhibitors
Alan Kozikowski et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
Susan C. Modesitt et al.
GYNECOLOGIC ONCOLOGY (2008)
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer
Johan Vansteenkiste et al.
INVESTIGATIONAL NEW DRUGS (2008)
Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors
Lillian L. Siu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors
Sheeba Varghese et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control
Srividya Bhaskara et al.
MOLECULAR CELL (2008)
HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation
R. B. Parmigiani et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer
George R. Blumenschein et al.
INVESTIGATIONAL NEW DRUGS (2008)
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
Guillermo Garcia-Manero et al.
BLOOD (2008)
Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications
Valeria R. Fantin et al.
CLINICAL CANCER RESEARCH (2007)
HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination
Shanthi Adimoolam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Histone deacetylase inhibitors: Overview and perspectives
Milos Dokmanovic et al.
MOLECULAR CANCER RESEARCH (2007)
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies
Shivaani Kummar et al.
CLINICAL CANCER RESEARCH (2007)
Histone deacetylase inhibitors selectively suppress expression of HDAC7
Milos Dokmanovic et al.
MOLECULAR CANCER THERAPEUTICS (2007)
The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells
J. Golay et al.
LEUKEMIA (2007)
HDAC6 modulates cell motility by altering the acetylation level of cortactin
Xiaohong Zhang et al.
MOLECULAR CELL (2007)
Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility
Rusty L. Montgomery et al.
GENES & DEVELOPMENT (2007)
Valproic acid (VPA) in patients with refractory advanced cancer:: a dose escalating phase I clinical trial
A. Atmaca et al.
BRITISH JOURNAL OF CANCER (2007)
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma
Madeleine Duvic et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Phase I and pharmacokinetic study of vorinostat, A histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies
Suresh S. Ramalingam et al.
CLINICAL CANCER RESEARCH (2007)
被撤回的出版物: Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation (Retracted article. See vol. 78, pg. 4097, 2018)
Chang-Shi Chen et al.
CANCER RESEARCH (2007)
Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents
H-S Lin et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines
Yasuhiko Kano et al.
INVESTIGATIONAL NEW DRUGS (2007)
Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug
Paul A. Marks et al.
NATURE BIOTECHNOLOGY (2007)
Functions of Site-Specific Histone Acetylation and Deacetylation
Mona D. Shahbazian et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2007)
Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors
Luis H. Camacho et al.
INVESTIGATIONAL NEW DRUGS (2007)
Thioredoxin and related molecules - From biology to health and disease
Christopher Horst Lillig et al.
ANTIOXIDANTS & REDOX SIGNALING (2007)
Pharmacological modulation of stem cell function
P. Romagnani et al.
CURRENT MEDICINAL CHEMISTRY (2007)
Thioredoxin in cancer - Role of histone deacetylase inhibitors
Paul A. Marks
SEMINARS IN CANCER BIOLOGY (2006)
Effects of histone deacetylase inhibitors on HIF-1
Dongming Liang et al.
CELL CYCLE (2006)
Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor
Weisheng Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The consensus coding sequences of human breast and colorectal cancers
Tobias Sjoeblom et al.
SCIENCE (2006)
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1α
David Z. Qian et al.
CANCER RESEARCH (2006)
Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of γ-H2AX foci
Anupama Munshi et al.
MOLECULAR CANCER THERAPEUTICS (2006)
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
Francis Giles et al.
CLINICAL CANCER RESEARCH (2006)
Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: A mechanism for leukemia-specific HDI-dependent apoptosis?
Terry J. Gaymes et al.
MOLECULAR CANCER RESEARCH (2006)
Phase I study of depsipeptide in pediatric patients with refractory solid tumors: A children's oncology group report
Maryam Fouladi et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10
Shurong Chang et al.
CELL (2006)
HDAC6-p97/VCP controlled polyubiquitin chain turnover
Cyril Boyault et al.
EMBO JOURNAL (2006)
Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors
Manisha H. Shah et al.
CLINICAL CANCER RESEARCH (2006)
Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma
Richard L. Piekarz et al.
CLINICAL CANCER RESEARCH (2006)
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition
S Ropero et al.
NATURE GENETICS (2006)
Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity
J Tan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1α
XG Kong et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Two catalytic domains are required for protein deacetylation
Y Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
OA O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Hsp90: A novel target for cancer therapy
David B. Solit et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2006)
Hydroxamide derivatives of short-chain fatty acid have erythropoietic activity and induce γ gene expression in vivo
H Cao et al.
EXPERIMENTAL HEMATOLOGY (2005)
Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes
CS Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast
ZH Zhang et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim
Y Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Induction of polyploidy by histone deacetylase inhibitor: A pathway for antitumor effects
WS Xu et al.
CANCER RESEARCH (2005)
Histone deacetylase inhibitors: insights into mechanisms of lethality
RR Rosato et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2005)
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 - A novel basis for antileukemia activity of histone deacetylase inhibitors
P Bali et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity
A Munshi et al.
CLINICAL CANCER RESEARCH (2005)
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
WK Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor
JJ Kovacs et al.
MOLECULAR CELL (2005)
Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin
AR Robbins et al.
CELL CYCLE (2005)
Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study
S Phuphanich et al.
NEURO-ONCOLOGY (2005)
Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors
MJ Peart et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Drug Insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid
WK Kelly et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2005)
Mitotic spindle checkpoint inactivation by trichostatin A defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents
M Dowling et al.
CANCER BIOLOGY & THERAPY (2005)
Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors
JS Ungerstedt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway
A Insinga et al.
NATURE MEDICINE (2005)
Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis
IV Gregoretti et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1
CY Gui et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications
CS Mitsiades et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Histone deacetylase inhibitors specifically kill nonproliferating tumour cells
A Burgess et al.
ONCOGENE (2004)
Regulation of histone deacetylase activities
N Sengupta et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2004)
Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells
S Nakata et al.
ONCOGENE (2004)
Apoptotic and autophagic cell death induced by histone deacetylase inhibitors
YF Shao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line
LG Wang et al.
ONCOGENE (2004)
Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases
JR Somoza et al.
STRUCTURE (2004)
Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor
A Vannini et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Cytochrome C-mediated apoptosis
XJ Jiang et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2004)
The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress
Y Kawaguchi et al.
CELL (2003)
Histone hyperacetylation in mitosis prevents sister chromatid separation and produces chromosome segregation defects
D Cimini et al.
MOLECULAR BIOLOGY OF THE CELL (2003)
Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5
A Rascle et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation
SJ Haggarty et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression
XJ Yang et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2003)
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease
E Hockly et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21CIP1/WAF1 promoter
JJ Westendorf et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin
LM Butler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression
G Lagger et al.
EMBO JOURNAL (2002)
Transcriptional regulation in acute promyelocytic leukemia
RJ Lin et al.
ONCOGENE (2001)
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species
AA Ruefli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins
PM Ayton et al.
ONCOGENE (2001)
Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases
A Taddei et al.
NATURE CELL BIOLOGY (2001)
Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation
VM Richon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
The role of the redox protein thioredoxin in cell growth and cancer
G Powis et al.
FREE RADICAL BIOLOGY AND MEDICINE (2000)
Share Paper
